Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Loss of function ABCG2 c.421C>A (rs2231142) polymorphism increases steady-state exposure to mycophenolic acid in stable renal transplant recipients: exploratory matched cohort study (CROSBI ID 317165)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Borić-Bilušić, Ana ; Božina, Nada ; Lalić, Zdenka ; Lovrić, Mila ; Nađ-Škegro, Sandra ; Penezić, Luka ; Barišić, Karmela ; Trkulja, Vladimir Loss of function ABCG2 c.421C>A (rs2231142) polymorphism increases steady-state exposure to mycophenolic acid in stable renal transplant recipients: exploratory matched cohort study // Advances in therapy, (2022), 1235; 12325, 18. doi: 10.1007/s12325-022-02378-w

Podaci o odgovornosti

Borić-Bilušić, Ana ; Božina, Nada ; Lalić, Zdenka ; Lovrić, Mila ; Nađ-Škegro, Sandra ; Penezić, Luka ; Barišić, Karmela ; Trkulja, Vladimir

engleski

Loss of function ABCG2 c.421C>A (rs2231142) polymorphism increases steady-state exposure to mycophenolic acid in stable renal transplant recipients: exploratory matched cohort study

Introduction. Polymorphism ABCG2 c.421C>A (rs2231142) results in a reduced activity of the important drug efflux transporter breast cancer resistance protein (BCRP/ABCG2). One study suggested that it may affect enterohepatic recirculation of mycophenolic acid (MPA). We evaluated the effect rs2231142 on steady-state exposure to MPA in renal transplant recipients. Methods. Consecutive, stable adult (age ≥16 years) renal transplant recipients on standard MPA-based immunosuppressant protocols (N=68, 43 co-treated with cyclosporine, 25 with tacrolimus) underwent routine therapeutic drug monitoring after a week of initial treatment, and were genotyped for ABCG2 c.421C>A and 11 polymorphisms in genes encoding enzymes and transporters implicated in MPA pharmacokinetics. ABCG2 c.421C>A variant vs. wild- type (wt) patients were matched in respect to demographic, biopharmaceutic and genetic variables (full optimal combined with exact matching) and compared for dose-adjusted steady-state MPA pharmacokinetics (frequentist and Bayes [skeptical neutral prior] estimates of geometric means ratios, GMR). Results. Raw data (12 variant vs. 56 wt patients) indicated by around 40% higher total exposure (frequentist GMR=1.45, 95%CI 1.10-1.91 ; Bayes = 1.38, 95%CrI 1.07-1.81) and by around 30% lower total body clearance (frequentist GMR=0.66, 0.58-0.90 ; Bayes=0.71, 0.53-0.95) in variant carriers than in wt controls. The estimates were similar in matched data (11 variant vs. 43 wt patients): exposure GMR=1.41 (1.11-1.79) frequentist, 1.39 (1.15-1.81) Bayes, with 90.7% and 85.5% probability of GMR >1.20, respectively ; clearance GMR=0.73 (0.58-0.93) frequentist, 0.71 (0.54-0.95) Bayes. Sensitivity analysis indicated high unsusceptibility of the estimates to unmeasured confounding. Conclusions. Loss-off- function polymorphism ABCG2 c.421C>A increases steady-state exposure to MPA in stable renal transplant patients.

mycophenolic acid, renal transplant, breast cancer resistance protein, polymorphism

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

(1235)

2022.

12325

18

objavljeno

0741-238X

10.1007/s12325-022-02378-w

Povezanost rada

nije evidentirano

Poveznice
Indeksiranost